Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Disease Area Metabolism & Diabetes, Animal models, Public health

Tackling the Fatty-Liver Timebomb

Affecting 1 in 5 today but with rising incidence, the medical community fear that non-alcoholic fatty liver disease (NAFLD) represents an increasingly serious public health threat (1) – especially as effective treatments are proving elusive. Now, researchers based at the University of Barcelona have published work on an oral therapeutic designed to modulate the activity of fibroblast growth factor (FGF21) – a key component in NAFLD pathology (2).

FGF21 exhibits strong anti-diabetic and, by extension, anti-fatty liver properties (3, 4) – conversely, growing resistance to FGF21 has been correlated with obesity and fat-related morbidities (5).

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Jonathan James

As an assistant editor for The Translational Scientist, I can combine two of my passions; translational science research and science communication. Having thrown myself into various editing and other science communication gigs whilst at University I came to realise the importance of good quality content that delivers in an exciting and engaging way.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register